Australia markets closed

Kraig Biocraft Laboratories, Inc. (KBLB)

OTC Markets OTCQB - OTC Markets OTCQB Delayed price. Currency in USD
Add to watchlist
0.1402-0.0067 (-4.56%)
At close: 03:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1469
Open0.1469
Bid0.1402 x 0
Ask0.1420 x 0
Day's range0.1402 - 0.1470
52-week range0.0300 - 0.1500
Volume177,496
Avg. volume1,170,992
Market cap145.579M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids

    ANN ARBOR, Mich., June 11, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness. The Company announced in early June that it had accelerated its production schedule for its new BAM-1 hybrids based on the results of its spring production trials. The rearing of this first batch of production hybrids is now wel

  • GlobeNewswire

    Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production

    ANN ARBOR, Mich., June 03, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids. The Company originally planned this launch for July, but the resounding successes of the production trials positioned Kraig Labs to accelerate its 2024 production schedule. This production cycle serves as a critical transition for the Company’s commercialization of

  • GlobeNewswire

    Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations

    Company Implementing Next Phase of Its Recombinant Spider Silk Business PlanANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness. Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the